Skeletal muscle-specific eukaryotic translation initiation factor 2α phosphorylation controls amino acid metabolism and fibroblast growth factor 21-mediated non-cell-autonomous energy metabolism.

Saved in:
Bibliographic Details
Title: Skeletal muscle-specific eukaryotic translation initiation factor 2α phosphorylation controls amino acid metabolism and fibroblast growth factor 21-mediated non-cell-autonomous energy metabolism.
Authors: Miyake M; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Nomura A; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Ogura A; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Takehana K; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Kitahara Y; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Takahara K; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Tsugawa K; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Miyamoto C; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Miura N; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Sato R; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Kurahashi K; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Harding HP; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Oyadomari M; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Ron D; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom., Oyadomari S; Division of Molecular Biology, Institute for Genome Research, and Department of Molecular Research, Diabetes Therapeutics and Research Center, The University of Tokushima, Tokushima, Japan; Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals Company, Limited, Kanagawa, Japan; and Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom oyadomar@tokushima-u.ac.jp.
Source: FASEB journal : official publication of the Federation of American Societies for Experimental Biology [FASEB J] 2016 Feb; Vol. 30 (2), pp. 798-812. Date of Electronic Publication: 2015 Oct 20.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Federation of American Societies for Experimental Biology Country of Publication: United States NLM ID: 8804484 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1530-6860 (Electronic) Linking ISSN: 08926638 NLM ISO Abbreviation: FASEB J Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1530-6860
DOI:10.1096/fj.15-275990